Acorda, Elan drug improves walking for MS patients

Acorda Therapeutics Inc. (ACOR.O: Quote, Profile, Research) said on Monday it will seek U.S. marketing approval early next year for the first medicine to improve walking among patients with multiple sclerosis, following highly favorable results of a second late-stage study.

Walk, wooble or roll here.

June 3, 2008 in follow the money..., press release, research, stocks, symptom management | Permalink | Comments (0)